This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Jan 1;25(1):1-2.

doi: 10.1200/JCO.2006.08.6462. Epub 2006 Dec 4.

On the road to new drugs in acute myeloid leukemia

PMID: 17146103
DOI: 10.1200/JCO.2006.08.6462

Editorial

On the road to new drugs in acute myeloid leukemia

Bob Löwenberg. J Clin Oncol. 2007.

. 2007 Jan 1;25(1):1-2.

doi: 10.1200/JCO.2006.08.6462. Epub 2006 Dec 4.

Author

PMID: 17146103
DOI: 10.1200/JCO.2006.08.6462

No abstract available

PubMed Disclaimer

Comment on

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S. Giles F, et al. J Clin Oncol. 2007 Jan 1;25(1):25-31. doi: 10.1200/JCO.2006.07.0961. Epub 2006 Dec 4. J Clin Oncol. 2007. PMID: 17146105 Clinical Trial.
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ. Roboz GJ, et al. J Clin Oncol. 2007 Jan 1;25(1):10-5. doi: 10.1200/JCO.2006.06.6209. Epub 2006 Dec 4. J Clin Oncol. 2007. PMID: 17146106 Clinical Trial.

Similar articles

Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.
Mayer RJ. Mayer RJ. Semin Oncol. 1987 Dec;14(4):384-96. Semin Oncol. 1987. PMID: 3321443 Review. No abstract available.
[State-of-the-art chemotherapy for acute myeloid leukemia].
Miyawaki S. Miyawaki S. Rinsho Ketsueki. 2012 Jan;53(1):39-50. Rinsho Ketsueki. 2012. PMID: 22374524 Review. Japanese. No abstract available.
Novel strategies for relapsed and refractory acute myeloid leukemia.
Mato AR, Morgans A, Luger SM. Mato AR, et al. Curr Opin Hematol. 2008 Mar;15(2):108-14. doi: 10.1097/MOH.0b013e3282f463d2. Curr Opin Hematol. 2008. PMID: 18300756 Review.
More on the treatment of relapsed acute myeloid leukemia.
Capizzi RL. Capizzi RL. Oncology (Williston Park). 1989 Oct;3(10):72-4. Oncology (Williston Park). 1989. PMID: 2701211 Review. No abstract available.
Why is clinical progress in acute myelogenous leukemia so slow?
Rowe JM. Rowe JM. Best Pract Res Clin Haematol. 2008 Mar;21(1):1-3. doi: 10.1016/j.beha.2007.11.001. Best Pract Res Clin Haematol. 2008. PMID: 18342806 No abstract available.

See all similar articles

Cited by

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia.
Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, He X, Lu W, Zhao M. Wei Y, et al. Front Oncol. 2020 Nov 5;10:584974. doi: 10.3389/fonc.2020.584974. eCollection 2020. Front Oncol. 2020. PMID: 33251145 Free PMC article. Review.
Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia.
Huang K, Sun Z, Ding B, Jiang X, Wang Z, Zhu Y, Meng F. Huang K, et al. Onco Targets Ther. 2019 Sep 11;12:7477-7488. doi: 10.2147/OTT.S216628. eCollection 2019. Onco Targets Ther. 2019. PMID: 31686853 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information